KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Non Operating Income: 2009-2024

Historic Non Operating Income for Vertex Pharmaceuticals (VRTX) over the last 16 years, with Dec 2024 value amounting to -$86.1 million.

  • Vertex Pharmaceuticals' Non Operating Income rose 42.01% to -$9.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.1 million, marking a year-over-year increase of 64.07%. This contributed to the annual value of -$86.1 million for FY2024, which is 277.63% down from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Non Operating Income of -$86.1 million as of FY2024, which was down 277.63% from -$22.8 million recorded in FY2023.
  • Vertex Pharmaceuticals' Non Operating Income's 5-year high stood at $296.6 million during FY2020, with a 5-year trough of -$164.8 million in FY2022.
  • Over the past 3 years, Vertex Pharmaceuticals' median Non Operating Income value was -$86.1 million (recorded in 2024), while the average stood at -$91.2 million.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Non Operating Income slumped by 3,463.27% in 2022 and then spiked by 86.17% in 2023.
  • Over the past 5 years, Vertex Pharmaceuticals' Non Operating Income (Yearly) stood at $296.6 million in 2020, then plummeted by 98.35% to $4.9 million in 2021, then plummeted by 3,463.27% to -$164.8 million in 2022, then spiked by 86.17% to -$22.8 million in 2023, then plummeted by 277.63% to -$86.1 million in 2024.